Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1992 1
1994 1
2001 1
2002 3
2003 2
2004 10
2005 7
2006 4
2007 7
2008 10
2009 6
2010 11
2011 6
2012 9
2013 6
2014 11
2015 10
2016 14
2017 17
2018 12
2019 14
2020 13
2021 13
2022 13
2023 11

Text availability

Article attribute

Article type

Publication date

Search Results

199 results

Results by year

Filters applied: . Clear all
Page 1
Psoriatic Arthritis.
Ritchlin CT, Colbert RA, Gladman DD. Ritchlin CT, et al. N Engl J Med. 2017 Mar 9;376(10):957-970. doi: 10.1056/NEJMra1505557. N Engl J Med. 2017. PMID: 28273019 Review. No abstract available.
Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial.
Deodhar A, Helliwell PS, Boehncke WH, Kollmeier AP, Hsia EC, Subramanian RA, Xu XL, Sheng S, Agarwal P, Zhou B, Zhuang Y, Ritchlin CT; DISCOVER-1 Study Group. Deodhar A, et al. Among authors: ritchlin ct. Lancet. 2020 Apr 4;395(10230):1115-1125. doi: 10.1016/S0140-6736(20)30265-8. Epub 2020 Mar 13. Lancet. 2020. PMID: 32178765 Free article. Clinical Trial.
Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.
Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, Dubreuil M, Dunham J, Husni ME, Kenny S, Kwan-Morley J, Lin J, Marchetta P, Mease PJ, Merola JF, Miner J, Ritchlin CT, Siaton B, Smith BJ, Van Voorhees AS, Jonsson AH, Shah AA, Sullivan N, Turgunbaev M, Coates LC, Gottlieb A, Magrey M, Nowell WB, Orbai AM, Reddy SM, Scher JU, Siegel E, Siegel M, Walsh JA, Turner AS, Reston J. Singh JA, et al. Among authors: ritchlin ct. Arthritis Rheumatol. 2019 Jan;71(1):5-32. doi: 10.1002/art.40726. Epub 2018 Nov 30. Arthritis Rheumatol. 2019. PMID: 30499246 Free PMC article.
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, van der Heijde D, Landewé R, Conaghan PG, Gottlieb AB, Richards H, Pricop L, Ligozio G, Patekar M, Mpofu S; FUTURE 2 Study Group. McInnes IB, et al. Among authors: ritchlin ct. Lancet. 2015 Sep 19;386(9999):1137-46. doi: 10.1016/S0140-6736(15)61134-5. Epub 2015 Jun 28. Lancet. 2015. PMID: 26135703 Free article. Clinical Trial.
Psoriatic Arthritis.
Ritchlin CT. Ritchlin CT. Rheum Dis Clin North Am. 2015 Nov;41(4):xiii-xiv. doi: 10.1016/j.rdc.2015.09.001. Rheum Dis Clin North Am. 2015. PMID: 26476232 No abstract available.
Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.
Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, Dubreuil M, Dunham J, Husni ME, Kenny S, Kwan-Morley J, Lin J, Marchetta P, Mease PJ, Merola JF, Miner J, Ritchlin CT, Siaton B, Smith BJ, Van Voorhees AS, Jonsson AH, Shah AA, Sullivan N, Turgunbaev M, Coates LC, Gottlieb A, Magrey M, Nowell WB, Orbai AM, Reddy SM, Scher JU, Siegel E, Siegel M, Walsh JA, Turner AS, Reston J. Singh JA, et al. Among authors: ritchlin ct. Arthritis Care Res (Hoboken). 2019 Jan;71(1):2-29. doi: 10.1002/acr.23789. Epub 2018 Nov 30. Arthritis Care Res (Hoboken). 2019. PMID: 30499259 Free PMC article. Review.
Does biologic therapy impact the development of PsA among patients with psoriasis?
Meer E, Merola JF, Fitzsimmons R, Love TJ, Wang S, Shin D, Chen Y, Xie S, Choi H, Zhang Y, Scher JU, Ritchlin CT, Gelfand JM, Ogdie A. Meer E, et al. Among authors: ritchlin ct. Ann Rheum Dis. 2022 Jan;81(1):80-86. doi: 10.1136/annrheumdis-2021-220761. Epub 2021 Oct 6. Ann Rheum Dis. 2022. PMID: 34615637
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.
Mease PJ, van der Heijde D, Ritchlin CT, Okada M, Cuchacovich RS, Shuler CL, Lin CY, Braun DK, Lee CH, Gladman DD; SPIRIT-P1 Study Group. Mease PJ, et al. Among authors: ritchlin ct. Ann Rheum Dis. 2017 Jan;76(1):79-87. doi: 10.1136/annrheumdis-2016-209709. Epub 2016 Aug 23. Ann Rheum Dis. 2017. PMID: 27553214 Free PMC article. Clinical Trial.
199 results